GAUCHER-DISEASE: payments to doctors
Payments that named GAUCHER-DISEASE as the associated drug or biological, reported under the Sunshine Act for program years 2019–2025.
Was your doctor paid by Sanofi?
Sanofi reported the most payments naming GAUCHER-DISEASE. Search your clinician to see whether they are among them — and what else they were paid for.
Finding a payment is not a finding of wrongdoing — most reported payments are a meal during a presentation. What matters is the kind, the size, and how it compares with their peers, which is what the profile shows.
- Total reported
- $12K
- Providers
- 592
- Transactions
- 658
- Average per transaction
- $18
The per-transaction average — $18 — is the number that tells you what kind of spending this is. A few dollars means meals at product presentations, reported by the thousand. Hundreds or thousands means consulting, speaking or royalty arrangements with a much smaller group of physicians. Across all 592 providers the average total is $20, but that average hides a very steep distribution.
Companies reporting these payments
| Company | Total reported | Share |
|---|---|---|
| Sanofi | $11,745 | 98.6% |
| Sanofi-aventis U.S. LLC | $168 | 1.4% |
Other products from Sanofi
The company that reported the most payments naming GAUCHER-DISEASE also reports against these.